phase 2
ii 2
study 1
alisertib 1
selective 1
aurora 1
kinase 1
inhibitor 1
relapsed 1
refractory 1
aggressive 1
b 1
tcell 1
nonhodgkin 1
lymphomas 1
multicenter 1
trial 1
hypercvad 1
mtxarac 1
rituximab 1
patients 1
previously 1
untreated 1
mantle 1
cell 1
lymphoma 1
swog 1
